Results 151 to 160 of about 53,405 (189)

Role of Imatinib Mesylate in Osteoblastogenesis.

Blood, 2007
Abstract Imatinib mesylate (IM), a tyrosine kinase inhibitor, currently used in chronic myeloid leukaemia (CML) may also affect the growth of other cellular systems besides CML cells. It has been reported that IM may affect bone tissue remodeling mainly by an inhibitory activity on osteoclastogenesis.
D. TIBULLO, C. GIALLONGO, P. LA CAVA, S. BERRETTA, F. STAGNO, A. CHIARENZA, G. A. PALUMBO, DI RAIMONDO, FRANCESCO   +7 more
openaire   +2 more sources

Effects of imatinib mesylate in osteoblastogenesis

Experimental Hematology, 2009
Imatinib mesylate (IM), a tyrosine kinase inhibitor currently used in chronic myeloid leukemia (CML), may also affect the growth of other cellular systems besides CML cells. Because it has been reported that IM may affect bone tissue remodeling, we evaluated the effects of IM on osteoblastic differentiation of human bone marrow mesenchymal stem cells ...
TIBULLO D, GIALLONGO C, LA CAVA P, BERRETTA S, STAGNO F, CHIARENZA A, CONTICELLO C, PALUMBO GA, DI RAIMONDO, FRANCESCO   +8 more
openaire   +3 more sources

Imatinib mesylate

American Journal of Health-System Pharmacy, 2001
openaire   +3 more sources

Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases.

Bone, 2017
F. Kaplan, Jeffrey R. Andolina, P. Adamson, D. Teachey, J. Finklestein, D. Ebb, B. Whitehead, B. Jacobs, D. Siegel, R. Keen, E. Hsiao, R. Pignolo   +11 more
semanticscholar   +1 more source

Controlled release and anti-proliferative effect of imatinib mesylate loaded sporopollenin microcapsules extracted from pollens of Betula pendula.

International Journal of Biological Macromolecules, 2017
I. Sargin, Lalehan Akyuz, M. Kaya, Gamze Tan, Talip Çeter, Kevser Yıldırım, Seymanur Ertosun, Gözde Hatun Aydın, Muge Topal   +8 more
semanticscholar   +1 more source

Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity.

Toxicology, 2017
Tara P Chambers, L. Santiesteban, David Gomez, J. Chambers   +3 more
semanticscholar   +1 more source

Nose‐to‐brain transport of imatinib mesylate: A pharmacokinetic evaluation

European Journal of Pharmaceutical Sciences, 2017
N. Hada, William J. Netzer, Fanny Belhassan, L. Wennogle, S. Gizurarson   +4 more
semanticscholar   +1 more source

Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes

Expert Review of Anticancer Therapy, 2016
F. Stagno, S. Stella, A. Spitaleri, M. Pennisi, F. Di Raimondo, P. Vigneri   +5 more
semanticscholar   +1 more source

A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor

Expert Opinion on Drug Safety, 2016
E. Ben Ami, G. Demetri
semanticscholar   +1 more source

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

Nature Medicine, 2006
Risto Kerkelä, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, Cara Beahm, B. Walters, S. Shevtsov, S. Pesant, F. Clubb, A. Rosenzweig, R. Salomon, R. A. Etten, J. Alroy, J. Durand, T. Force   +15 more
semanticscholar   +1 more source